Merck now says molnupiravir reduces the risk of hospitalization or death from COVID-19 by 30% after all data have been analyzed. Previously, an interim analysis showed a 50% reduction in hospitalization or death.
Formulary Watch
Latest News
All News
Advertisement
Moderna and Pfizer are assessing their vaccines against the Omicron variant, which was first identified in South Africa.
Across all payers, the use of generic statins has resulted in a savings of $11.9 billion annually.
New requirements resulted in long call wait times, which has led to patient access issues.
Patients who are part of the Walgreen’s Prescription Savings Club can receive Semglee at up to 80% off the cash price.
Livtencity is the first therapy approved to treat cytomegalovirus infection, which is common after transplants.
The incidence of brain swelling was highest in the group of patients who received the highest doses of Aduhelm, as well as the group of patients who are carriers of the APoE gene.
OptumRx will favor the reference product Lantus on the Premium Formulary. The organization also released coverage information about other newly approved therapies.
Several new generics have launched in the United States, including for the migraine therapy Zomig, the anticancer therapy Doxil, and an anti-inflammatory used to treat respiratory conditions associated with COVID-19.
If approved, Bluebird Bio’s beti-cel would be the first one-therapy for β-thalassemia. The PDUFA date is May 20, 2022.
Advertisement
Pfizer/BioNTech plan to use this data to support submissions for full approval of the vaccine in those 12 to 15 years old.
The antiseizure medication affected by the recall could have sterility issues.
Bulevirtide has been granted breakthrough therapy and orphan drug designations by the FDA.
BioMarin’s Voxzogo is expected to be available in the United States by mid- to late-December.
The boosters are now authorized for all people 18 years of age and older.
The FDA needs additional time to assess information about proposed risk revaluation mitigation strategy for the treatment for obstructive hypertrophic cardiomyopathy.
Besremi was approved recently to treat a rare blood disease.
Keytruda is the first immunotherapy approved for treatment of patients with early renal cell carcinoma after surgery.
Most of the patients with no immune response after the two-dose regimen responded well to a third shot.
ICER’s review indicates that Humira’s price increases are not supported by new clinical evidence.
If authorized, Paxlovid would be the first oral 3CL protease inhibitor specifically designed to combat the virus that causes COVID-19.
Branded and unbranded versions of the interchangeable biosimilar to treat patients with diabetes are now available.
A reimbursement policy similar to that used for branded and generic drugs would have saved $1.6 billion from 2015 to 2019.
Equipment and process issues could lead to a lack of sterility.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Arpit Patel. Pharm.D., MedImpact
2
Investigational non-opioid LTG-001 reduced acute pain in phase 2b trial
3
Ashley Holzworth-Nash, Pharm.D., Evernorth
4
CMS Medicaid Fraud War Room stops more than $203 million in improper payments
5